- Genmab shares surged 29% to $57.52 on Wednesday
- petosemtamab plus Keytruda cut death risk by 50% in recurrent/metastatic head and neck cancer
Genmab's U.S.-listed shares jumped 29% to $57.52 after trial data showed petosemtamab plus Keytruda cut death risk by 50% in head and neck cancer. The company plans global regulatory engagement.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.